Literature DB >> 26303611

Infantile Refsum Disease: Influence of Dietary Treatment on Plasma Phytanic Acid Levels.

Maria João Nabais Sá1,2, Júlio C Rocha3,4,5, Manuela F Almeida6,3, Carla Carmona7,6, Esmeralda Martins6,8, Vasco Miranda9, Miguel Coutinho10, Rita Ferreira11, Sara Pacheco11, Francisco Laranjeira11, Isaura Ribeiro6,11, Ana Maria Fortuna7,6, Lúcia Lacerda6,11.   

Abstract

Infantile Refsum disease (IRD) is one of the less severe of Zellweger spectrum disorders (ZSDs), a group of peroxisomal biogenesis disorders resulting from a generalized peroxisomal function impairment. Increased plasma levels of very long chain fatty acids (VLCFA) and phytanic acid are biomarkers used in IRD diagnosis. Furthermore, an increased plasma level of phytanic acid is known to be associated with neurologic damage. Treatment of IRD is symptomatic and multidisciplinary.The authors report a 3-year-old child, born from consanguineous parents, who presented with developmental delay, retinitis pigmentosa, sensorineural deafness and craniofacial dysmorphisms. While the relative level of plasma C26:0 was slightly increased, other VLCFA were normal. Thus, a detailed characterization of the phenotype was essential to point to a ZSD. Repeatedly increased levels of plasma VLCFA, along with phytanic acid and pristanic acid, deficient dihydroxyacetone phosphate acyltransferase activity in fibroblasts and identification of the homozygous pathogenic mutation c.2528G>A (p.Gly843Asp) in the PEX1 gene, confirmed this diagnosis. Nutritional advice and follow-up was proposed aiming phytanic acid dietary intake reduction. During dietary treatment, plasma levels of phytanic acid decreased to normal, and the patient's development evaluation showed slow progressive acquisition of new competences.This case report highlights the relevance of considering a ZSD in any child with developmental delay who manifests hearing and visual impairment and of performing a systematic biochemical investigation, when plasma VLCFA are mildly increased. During dietary intervention, a biochemical improvement was observed, and the long-term clinical effect of this approach needs to be evaluated.

Entities:  

Keywords:  Dietary treatment; Infantile Refsum disease; Peroxisomal biogenesis disorder; Phytanic acid; Psychomotor development; Very long chain fatty acids

Year:  2015        PMID: 26303611      PMCID: PMC4864718          DOI: 10.1007/8904_2015_487

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  25 in total

1.  Reinvestigation of trihydroxycholestanoic acidemia reveals a peroxisome biogenesis disorder.

Authors:  J Gootjes; F Skovby; E Christensen; R J A Wanders; S Ferdinandusse
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

2.  Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder.

Authors:  Merel S Ebberink; Petra A W Mooijer; Jeannette Gootjes; Janet Koster; Ronald J A Wanders; Hans R Waterham
Journal:  Hum Mutat       Date:  2011-01       Impact factor: 4.878

3.  A novel PEX12 mutation identified as the cause of a peroxisomal biogenesis disorder with mild clinical phenotype, mild biochemical abnormalities in fibroblasts and a mosaic catalase immunofluorescence pattern, even at 40 degrees C.

Authors:  Avraham Zeharia; Merel S Ebberink; Ronald J A Wanders; Hans R Waterham; Alisa Gutman; Andreea Nissenkorn; Stanley H Korman
Journal:  J Hum Genet       Date:  2007-05-30       Impact factor: 3.172

Review 4.  Metabolic functions of peroxisomes in health and disease.

Authors:  Ronald J A Wanders
Journal:  Biochimie       Date:  2013-09-03       Impact factor: 4.079

Review 5.  Peroxisomal disorders.

Authors:  Patrick Aubourg; Ronald Wanders
Journal:  Handb Clin Neurol       Date:  2013

Review 6.  Phytanic acid metabolism in health and disease.

Authors:  Ronald J A Wanders; Jasper Komen; Sacha Ferdinandusse
Journal:  Biochim Biophys Acta       Date:  2011-06-13

Review 7.  Peroxisome biogenesis disorders: Biological, clinical and pathophysiological perspectives.

Authors:  Nancy E Braverman; Maria Daniela D'Agostino; Gillian E Maclean
Journal:  Dev Disabil Res Rev       Date:  2013

8.  Plasma and red blood cell fatty acids in peroxisomal disorders.

Authors:  A B Moser; D S Jones; G V Raymond; H W Moser
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

9.  Treatment of infantile phytanic acid storage disease: clinical, biochemical and ultrastructural findings in two children treated for 2 years.

Authors:  E F Robertson; A Poulos; P Sharp; J Manson; G Wise; A Jaunzems; R Carter
Journal:  Eur J Pediatr       Date:  1988-02       Impact factor: 3.183

10.  Validation of a rapid measure of blood PUFA levels in humans.

Authors:  Eileen Bailey-Hall; Edward B Nelson; Alan S Ryan
Journal:  Lipids       Date:  2007-12-15       Impact factor: 1.880

View more
  1 in total

1.  Molecular effects of the consumption of margarine and butter varying in trans fat composition: a parallel human intervention study.

Authors:  Dominik Guggisberg; Kathryn J Burton-Pimentel; Barbara Walther; René Badertscher; Carola Blaser; Reto Portmann; Alexandra Schmid; Thomas Radtke; Hugo Saner; Nadine Fournier; Ueli Bütikofer; Guy Vergères
Journal:  Lipids Health Dis       Date:  2022-08-18       Impact factor: 4.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.